Download Files:

Allisartan isoproxil

$200$1,900

Products Details

Product Description

– Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1. Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs[1][2].

Web ID

– HY-111032

Storage Temperature

– 4°C (Powder, protect from light)

Shipping

– Room Temperature

Molecular Formula

– C27H29ClN6O5

References

– [1]Liu Y, et al. A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats. Drug Chem Toxicol. 2013 Oct;36(4):443-50. |[2]Ling QS, et al. Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage. Acta Pharmacol Sin. 2021 Jun;42(6):871-884.

CAS Number

– 947331-05-7

Molecular Weight

– 553.01

Compound Purity

– 99.12

SMILES

– O=C(C1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)OCOC(OC(C)C)=O

Clinical Information

– Phase 4

Research Area

– Cardiovascular Disease

Solubility

– DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– Angiotensin Receptor

Isoform

– AT1 Receptor

Pathway

– GPCR/G Protein

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.